Educational & Guideline Reference Notice: Unranked FDA-label and national guideline option categories and recruiting clinical trials for discussion with a licensed oncologist. Protocol drug dosing and autonomous treatment prescriptions are excluded.
Ovarian, Fallopian Tube & Primary Peritoneal Cancer — Options & Clinical Trial Reference
Source-cited reference covering germline/somatic BRCA1/2, HRD status, Folate Receptor-alpha (FRa), platinum interval, maintenance categories, and recruiting trials.
Key Biomarkers & Decision Factors:
biomarkerspending_status_valuesequivocal_valuesversionstatuscarried_from
biomarkerspending_status_valuesequivocal_valuesversionstatuscarried_from
Unranked Guideline & FDA-Label Option Categories (22 total)
| Option / Pathway | Category | Primary Sources |
|---|---|---|
| Mirvetuximab soravtansine | selected_indicated_therapy | mirv, mirv-label |
| Pembrolizumab + paclitaxel ± bevacizumab | selected_indicated_therapy | pembro, pembro-label, paclitaxel-label, bev-label |
| Relacorilant + nab-paclitaxel | selected_indicated_therapy | rela, rela-label, nab-paclitaxel-label |
| Paclitaxel (single agent) | conventional_therapy | nci, paclitaxel-label |
| Pegylated liposomal doxorubicin (single agent) | conventional_therapy | nci, pld-label |
| Topotecan (single agent) | conventional_therapy | nci, topotecan-label |
| Gemcitabine (single agent; off-label here) | conventional_therapy | nci, gemcitabine-label |
| Bevacizumab + paclitaxel | selected_indicated_therapy | bev-label, nci, paclitaxel-label |
| Bevacizumab + pegylated liposomal doxorubicin | selected_indicated_therapy | bev-label, nci, pld-label |
| Bevacizumab + topotecan | selected_indicated_therapy | bev-label, nci, topotecan-label |
| Pembrolizumab alone (MSI-H or dMMR solid tumours) | selected_indicated_therapy | pembro-msi-label |
| Dostarlimab alone (dMMR solid tumours) | selected_indicated_therapy | jemperli-label-v15-selection, ventana-p210001-jemperli, mi-cancer-seek-p240010-jemperli, dostarlimab-label |
| Trastuzumab deruxtecan alone (HER2 IHC 3+ solid tumours) | selected_indicated_therapy | tdxd-label |
| Clinical-trial review | care_pathway | nci |
| Supportive and palliative care review | care_pathway | palliative |
View all 22 Ovarian, Fallopian Tube & Primary Peritoneal Cancer reference options →
Recruiting Clinical Trials (342 curated)
| NCT ID | Study Title | Phase |
|---|---|---|
| NCT00539162 | Use of CA125 and Complementary Biomarkers for the Early Detection of Ovarian Cancer in Low Risk Women | NA |
| NCT01174121 | Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Cancer | PHASE2 |
| NCT01558544 | Cryopreservation of Ovarian Tissue | NA |
| NCT02830724 | Administering Peripheral Blood Lymphocytes Transduced With a CD70-Binding Chimeric Antigen Receptor to People With CD70 Expressing Cancers | PHASE1|PHASE2 |
| NCT03011684 | Fertility Preservation Using Tamoxifen and Letrozole in Estrogen Sensitive Tumors Trial | PHASE3 |
| NCT03067181 | Active Surveillance, Bleomycin, Etoposide, Carboplatin or Cisplatin in Treating Pediatric and Adult Patients With Germ Cell Tumors | PHASE3 |
| NCT03412877 | Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in People With Metastatic Cancer | PHASE2 |
| NCT03544983 | Genetic Education in BRCA Families | NA |
| NCT03564340 | Study of REGN4018 (Ubamatamab) Administered Alone or in Combination With Cemiplimab in Adult Patients With Recurrent Ovarian Cancer or Other Recurrent Mucin-16 Expressing (MUC16+) Cancers | PHASE1|PHASE2 |
| NCT03604315 | Serial Imaging of the Novel Radiotracer [^18F] FLuorthanatrace ([^18F] FTT) by PET/CTF | PHASE1 |
| NCT03686124 | ACTengine® IMA203/IMA203CD8 as Monotherapy or in Combination With Nivolumab in Recurrent and/or Refractory Solid Tumors | PHASE1|PHASE2 |
| NCT03854110 | A Trial to Evaluate Safety, Tolerability, and Preliminary Efficacy of Misetionamide (GP-2250) as Monotherapy or in Combination With Gemcitabine | PHASE1 |
View all 342 Ovarian, Fallopian Tube & Primary Peritoneal Cancer clinical trials →